Casdin Capital Portfolio
Casdin Capital 13F filer (CIK 0001534261).
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q2 2020 · 42 positions · Total reported value $1.69B · Top-10 concentration 59.6% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 26.1% · 6 new · 3 cut · 3 exited
Active Share (vs S&P 500): 99.8% · vs QQQ: 99.9% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q1 2026 → Q2 2026): +47.2% · vs SPY +32.4% · Prev Value $1.32B — last quarter positions weighted by this quarter price moves · ranking
In its Q2 2020 13F filing, Casdin Capital disclosed 42 equity positions with a combined reported value of $1.69B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 59.6% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.
The largest disclosed positions as of Q2 2020 were NVTAQ ($273.64M), BPMC ($120.90M), FATE ($104.65M). By sector, the heaviest allocations are Health Care 50.2%, Industrials 3.2%. Versus the prior quarter, allocation shifted toward Other (+5.2pp) and away from Health Care (-2.4pp), Industrials (-2.8pp).
Versus the prior quarter, Casdin Capital opened 6 new positions, trimmed 3 and fully exited 3, a turnover rate of 26.1% of positions. The portfolio's overlap with the prior quarter was 78% of names.
The largest new positions opened in Q2 2020 were BNR ($46.75M), GBIO ($33.84M), ONC ($28.26M).
Of the 3 positions fully exited versus the prior quarter, the largest were GNMK ($13.86M), GILD ($13.08M), SAGE ($11.06M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q2 2020)
- BNR BURNING ROCK BIOTECH LTD · $46.75M
- GBIO GENERATION BIO CO · $33.84M
- ONC BEONE MEDICINES LTD · $28.26M
- AMRSQ AMYRIS INC · $22.84M
- ORIC ORIC PHARMACEUTICALS INC · $8.48M
- LEGN LEGEND BIOTECH CORP SPONSORED ADS · $5.75M
- ZYME ZYMEWORKS INC COM · $4.69M
Insider Transactions (Form 4)
Latest Casdin Capital buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
Casdin Capital is an SEC-registered 13F filer based in New York, NY, United States. As of Q2 2026 it reported 43 US equity positions with a combined value of $2.00B. HoldingsHub carries 43 quarters of its filings (Q4 2015–Q2 2026).
Firm Snapshot
- Headquarters: NEW YORK, NY, United States
- SEC registration: 801-110894 (status: Approved), registered 2017-07-31
- Regulatory AUM (Form ADV): $2.87B as of 2026-03-31
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 5 private funds, of which 2 hedge funds
Portfolio Structure
- 43 positions · $2.00B reported value (Q2 2026)
- Top 10 holdings = 77.4% of reported value
- Largest position: RVMD (REVOLUTION MEDICINES INC) at 24.2%
- Average position size: $46.46M
Sector Tilt
- Health Care 94.2%
- Industrials 5.7%
- (classified holdings cover 100% of value)
Quarterly Activity
- Q2 2026: 6 new, 9 added, 3 reduced, 3 exited
- 25 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
9.03M | $273.64M | 16.19% | Add | |
| 2 |
|
1.55M | $120.90M | 7.16% | Hold | |
| 3 |
|
3.05M | $104.65M | 6.19% | Add | |
| 4 |
|
530.00K | $84.98M | 5.03% | Reduce | |
| 5 |
|
870.00K | $84.06M | 4.97% | Reduce | |
| 6 |
|
550.00K | $81.46M | 4.82% | Reduce | |
| 7 |
|
4.85M | $79.29M | 4.69% | Add | |
| 8 |
|
1.10M | $67.45M | 3.99% | Hold | |
| 9 |
|
1.07M | $57.22M | 3.39% | Hold | |
| 10 |
|
4.69M | $53.50M | 3.17% | Reduce | |
| 11 |
|
1.73M | $46.75M | 2.77% | New | |
| 12 |
|
1.00M | $45.30M | 2.68% | Hold | |
| 13 |
|
1.19M | $42.28M | 2.50% | Reduce | |
| 14 |
|
1.33M | $42.13M | 2.49% | Add | |
| 15 |
|
1.86M | $38.94M | 2.31% | Add | |
| 16 |
|
713.12K | $34.50M | 2.04% | Reduce | |
| 17 |
|
1.61M | $33.84M | 2.00% | New | |
| 18 |
|
1.31M | $31.68M | 1.88% | Reduce | |
| 19 |
|
980.00K | $29.45M | 1.74% | Hold | |
| 20 |
|
150.00K | $28.26M | 1.67% | New | |
| 21 |
|
625.00K | $26.76M | 1.58% | Add | |
| 22 |
|
1.44M | $26.36M | 1.56% | Add | |
| 23 |
|
1.08M | $26.30M | 1.56% | Hold | |
| 24 |
|
3.35M | $25.13M | 1.49% | Add | |
| 25 |
|
5.35M | $22.84M | 1.35% | New | |
| 26 |
|
266.43K | $19.58M | 1.16% | Hold | |
| 27 |
|
300.00K | $18.94M | 1.12% | Hold | |
| 28 |
|
1.43M | $18.90M | 1.12% | Add | |
| 29 |
|
190.00K | $15.61M | 0.92% | Hold | |
| 30 |
|
1.46M | $13.04M | 0.77% | Hold | |
| 31 |
|
1.85M | $12.29M | 0.73% | Reduce | |
| 32 |
|
289.39K | $12.20M | 0.72% | Hold | |
| 33 |
|
30.00K | $11.11M | 0.66% | Hold | |
| 34 |
|
2.95M | $10.56M | 0.62% | Add | |
| 35 |
|
1.65M | $9.90M | 0.59% | Add | |
| 36 |
|
750.00K | $9.46M | 0.56% | Reduce | |
| 37 |
|
251.51K | $8.48M | 0.50% | New | |
| 38 |
|
135.00K | $5.75M | 0.34% | New | |
| 39 |
|
75.00K | $4.84M | 0.29% | Hold | |
| 40 |
|
130.00K | $4.69M | 0.28% | New | |
| 41 |
|
65.00K | $3.88M | 0.23% | Reduce | |
| 42 |
|
120.00K | $2.86M | 0.17% | Hold | |
FAQ
What did Casdin Capital buy in 2020-Q2?
In its 2020-Q2 13F filing, Casdin Capital reported 42 equity positions worth $1.69B in aggregate; its largest disclosed positions were NVTAQ ($273.64M), BPMC ($120.90M), FATE ($104.65M).
How large is Casdin Capital's portfolio?
Casdin Capital reported $1.69B of long equity holdings across 42 positions as of 2020-Q2. Top-10 holdings account for 59.6% of reported value.
What is Casdin Capital's investment style?
HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.